

**European Conference on Risk-Stratified Prevention and  
Early Detection of Breast Cancer  
(Tirol/Austria)**

**Day 0 (25.6.2019):**

**F2F Meetings for FORECEE (n=25), BRIDGES (n=25), MyPeBS (n=20) and B-CAST (n=25) Consortia**

<b>Day 1 (26.6.2019)</b>		
08.30-08.40	<ul style="list-style-type: none"> <li>Introduction / Welcome.</li> </ul>	<ul style="list-style-type: none"> <li>Martin Widschwendter</li> </ul>
08.40-09.00	<ul style="list-style-type: none"> <li>'Where do we want to go?' Set the European vision for risk-stratified prevention and early detection of breast cancer.</li> </ul>	<ul style="list-style-type: none"> <li>Laura Biganzoli (President EUSOMA)</li> </ul>
09.00-09.10	<ul style="list-style-type: none"> <li>Introduce the various pieces of the jigsaw that will ultimately achieve the vision.</li> </ul>	<ul style="list-style-type: none"> <li>Nora Pashayan</li> </ul>
09.10-10.00	<p><b>Introduction</b> to the different projects (10 minutes each). 'Where are we now?' Short introduction to each of the projects in order to set the scene and to explain which part of the jigsaw is covered by each individual project (I would suggest we produce an overview indicating which project covers which particular piece of the jigsaw).</p>	
09.10-09.20	<ul style="list-style-type: none"> <li>B-CAST</li> </ul>	<ul style="list-style-type: none"> <li>Marjanka Schmidt</li> </ul>
09.20-09.30	<ul style="list-style-type: none"> <li>BRIDGES</li> </ul>	<ul style="list-style-type: none"> <li>Peter Devilee</li> </ul>
09.30-09.40	<ul style="list-style-type: none"> <li>FORECEE &amp; BRCA-ERC</li> </ul>	<ul style="list-style-type: none"> <li>Martin Widschwendter</li> </ul>
09.40-09.50	<ul style="list-style-type: none"> <li>MyPeBS</li> </ul>	<ul style="list-style-type: none"> <li>Suzette Delalogue</li> </ul>
09.50-10.00	<ul style="list-style-type: none"> <li>EU-TOPIA</li> </ul>	<ul style="list-style-type: none"> <li>Harry de Koning</li> </ul>
10.00-11.10	<p>Breast cancer <b>risk prediction</b>.</p>	<p>Chair: Peter Devilee &amp; Marjanka Schmidt</p>
10.00-10.40	<ol style="list-style-type: none"> <li>Presentation describing the different risk prediction models (based on pathogenic hereditary mutations, polygenic risk, epidemiological risk factors including mammographic density, predicting single disease or multiple disease simultaneously, predicting different subtypes of disease with different prognosis); the stage at which they currently are (development or validation) and how efficient they are in determining risk-stratification.</li> </ol>	<ol style="list-style-type: none"> <li>Antonis Antoniou</li> </ol>
10.40-10.55	<ol style="list-style-type: none"> <li>Risk prediction model based on epigenetics.</li> </ol>	<ol style="list-style-type: none"> <li>Martin Widschwendter</li> </ol>
10.55-11.10	<ol style="list-style-type: none"> <li>Future directions.</li> </ol>	<ol style="list-style-type: none"> <li>Doug Easton</li> </ol>
11.10-11.45	<p>Coffee break.</p>	
11.45-12.00	<p>Discussion – identify gaps in research with respect to risk prediction modelling.</p>	<p>Peter Devilee &amp; Marjanka Schmidt</p>
12.00-13.25	<p>Risk-stratification for the <b>prevention</b> of breast cancer at the population level.</p>	<p>Chair: Jack Cuzick</p>
12.00-12.40	<ol style="list-style-type: none"> <li>Presentation regarding the latest evidence from current practice;</li> </ol>	<ol style="list-style-type: none"> <li>Per Hall</li> </ol>

	randomised trials; modelling studies; prevention modalities; strength of evidence; endpoints utilised; eligibility for prevention (how high risk is defined) and endpoints.	
12.40-12.55	2. Potential new targets for prevention.	2. Martin Widschwendter
12.55-13.10	3. Lifestyle modification in order to reduce the risk of developing breast cancer.	3. Montse Garcia Closas
13.10-13.25	4. Clinical application model for stratified prevention (in BRCA carriers).	4. Rita Schmutzler
13.25-14.25	Lunch.	
14.25-14.40	Discussion - identify gaps in research with respect to risk-stratified prevention (including drugs and intermediate endpoints, etc.).	Jack Cuzick
14.40-15.45	Risk-stratification for the <b>early detection</b> of breast cancer at the population level (covering proxy outcomes, risk thresholds for risk classification and screening strategies and any results from trials, population studies and modelling studies).	Chair: Harry de Koning
14.40-14.50	1. MyPeBS Trial.	1. Suzette Delalogue
14.50-15.05	2. WISDOM Trial.	2. Laura Esserman
15.05-15.20	3. PERSPECTIVE I&I Study.	3. Jacques Simard
15.20-15.35	4. PROCAS Study.	4. Gareth Evans
15.35-15.45	5. Modelling studies.	5. Nora Pashayan
15.45-16.00	Discussion - identify gaps in research with respect to risk-stratified screening (including varying screening intervals, etc.).	Harry de Koning
16.00-16.30	Coffee break.	
16.30-17.45	<b>Implementation</b> related: Evidence from different Consortia related to:	Chair: Nora Pashayan
16.30-16.45	1. Economic evaluation.	1. Gaby Sroczynski
16.45-17.00	2. Acceptability surveys.	2. Odette Wegwarth
17.00-17.15	3. Communication, decision aids.	3. David French
17.15-17.30	4. Policy landscape.	4. Sowmiya Moorthie
17.30-17.45	5. ELSI challenges.	5. Inez de Beaufort
17.45-18.00	Discussion - identify gaps in research related to implementation.	Nora Pashayan
19.30-22.30	Public Engagement Event in Innsbruck (Dogana/Congress).	
<b>Day 2 (27.6.2019)</b>		
09.00-09.30	Setting the European Agenda: European strategies for the advancement of personalised early detection and prevention of cancer.	Sasa Jenko Kokalj (Head of Sector at the European Commission, Advancing Public Health Research)

09.30-10.00	<p>Summary of day 1.</p> <ul style="list-style-type: none"> <li>• Where we are in relation to the various pieces of the jigsaw.</li> <li>• Identifying the gaps in research.</li> <li>• The plan for the day (Breakout Sessions 1 and 2).</li> </ul>	Marjanka Schmidt & Martin Widschwendter
10.00-11.30	<p>Breakout Session 1 (coffee will be served).</p> <ul style="list-style-type: none"> <li>• How to close the various gaps in research evidence and thus determine the future direction of research with respect to prevention and early detection, risk assessment, clinical validity and clinical utility. <ul style="list-style-type: none"> <li>- Research questions.</li> <li>- Types of research studies (randomised trials, modelling).</li> <li>- Research endpoints.</li> <li>- How to establish these studies.</li> </ul> </li> </ul> <p>Three groups will cover the aforementioned topics:</p> <ul style="list-style-type: none"> <li>- Group 1: Risk assessment (LEAD: Peter Devilee + Antonis Antoniou).</li> <li>- Group 2: Early detection (LEAD: Suzette Delalogue + Rita Schmutzler).</li> <li>- Group 3: Prevention (LEAD: Per Hall + Gareth Evans).</li> </ul>	
11.30-13.30	<p>Lunch with SME's who specifically address unmet needs and areas which are unlikely to be covered in Day 1 or Day 2 (5-8 SMEs will present their topics for 10-15 minutes each).</p>	<p>To be confirmed:</p> <ul style="list-style-type: none"> <li>- Evidencio</li> <li>- Alamut – Interactive Biosoftware</li> <li>- Predilife (multi risk assessment and density software)</li> <li>- Eonix (health communication webplatform)</li> </ul>
13.30-15.00	<p>Breakout Session 2.</p> <ul style="list-style-type: none"> <li>• Integration into clinical practice? What are the critical issues, how will service providers and users be engaged and what strategies and policy documents must be in place? <ul style="list-style-type: none"> <li>- What frameworks need to be in place?</li> <li>- How to build on existing infrastructure?</li> <li>- Economic aspects, SME engagement.</li> <li>- What can we learn from EU-TOPIA?</li> </ul> </li> </ul> <p>Three groups will cover the aforementioned topics:</p> <ul style="list-style-type: none"> <li>- Group 1: Engaging stakeholders (scientific community, providers, users to “buy in” with associated political commitment) (LEAD: Harry de Koning &amp; David Ritchie).</li> <li>- Group 2: Healthcare organisation readiness (LEAD: Nora Pashayan &amp; Sven Tornberg).</li> <li>- Group 3: ELSI considerations (LEAD: Inez de Beaufort &amp; Sandrine De Montgolfier).</li> </ul>	
15.00-16.00	Coffee break.	
16.00-18.00	Presentation encompassing all discussions from the breakout sessions.	Coordination – Martin Widschwendter & Marjanka Schmidt.

		Presentations by each lead of the 6 groups.
18.00-22.00	Working Dinner to prepare for Day 3 – Position Statement.	
<b>Day 3 (28.6.2019)</b>		
09.00-10.00	Keynote Lecture: Europe's Challenges and Ways to Address Them.	Dr Franz Fischler (former European Union Commissioner for Agriculture, Rural Development and Fisheries (1995 to 2005 – during which time Dr Fischler managed the BSE crisis).
10.00-11.15	<p>Position Statement with respect to the topics detailed below (lead in brackets). Each presentation will be 5 minutes in duration (3-4 slides) followed by 3 minutes of discussion:</p> <ul style="list-style-type: none"> <li>- Genetic Risk (Doug Easton).</li> <li>- Epigenetic Risk (Martin Widschwendter).</li> <li>- Classical Risk Factors (Matti Rookus).</li> <li>- Risk Prediction (Paul Pharoah).</li> <li>- Breast Cancer Subtypes (Jelle Wesseling).</li> <li>- Imaging (Ruud Pijnappel).</li> <li>- Alternative Early Diagnostic Tools (Zdenko Herceg).</li> <li>- Prevention (Gareth Evans).</li> <li>- Specific Aspects in High Risk Women (Clare Turnbull).</li> </ul> <p>The following three questions will be addressed when discussing each of the above topics:</p> <ul style="list-style-type: none"> <li>• Where we are?</li> <li>• Where we want to go?</li> <li>• How to get there?</li> </ul>	
11.15-11.30	Coffee break.	
11.30-12.45	<p>Position Statement with respect to the topics detailed below (lead in brackets). Each presentation will be 5 minutes in duration (3-4 slides) followed by 3 minutes of discussion:</p> <ul style="list-style-type: none"> <li>- Outcome (Stefan Michiels).</li> <li>- Trial Logistics (Suzette Delaloge).</li> <li>- Implementation (Nora Pashayan).</li> <li>- Economical Evaluation (Gaby Sroczyński).</li> <li>- Communication and Decision Aids (Odette Wegwarth).</li> <li>- Policy Landscape and Funding (Hilary Burton).</li> <li>- ELSI Challenges (Sandrine De Montgolfier).</li> <li>- Workforce Training (David Ritchie).</li> <li>- Healthcare Organisation Readiness (Sven Tornberg).</li> </ul> <p>The following three questions will be addressed when discussing each of the above topics:</p> <ul style="list-style-type: none"> <li>• Where we are?</li> <li>• Where we want to go?</li> <li>• How to get there?</li> </ul>	
12.45-13.45	Lunch.	
14.00-19.00 (& possibly	Social Event (taking the cable car into the mountains with a view to hiking, socialising and discussing and generating new ideas in a relaxed	

open ended)	and exceptionally picturesque setting).	
-------------	---	--

\*Leading to a joint review/perspective paper (MW to contact Nature Reviews Cancer in order to ascertain whether the Editor would consider an opinion/perspective paper based on the outcomes of the ENVISION Conference).

PRELIMINARY